Diastolic dysfunction in hypertensive hearts: Roles of perivascular inflammation and reactive myocardial fibrosis

Hypertension Research

Volumn 28, Issue 6, 2005, Pages 483-490

  Kai, Hisashi ^a   Kuwahara, Fumitaka ^a   Tokuda, Keisuke ^a   Imaizumi, Tsutomu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II; Hypertension; Inflammation; Macrophages; Myocardial fibrosis

Indexed keywords

ANGIOTENSIN; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA;

AORTA CONSTRICTION; CELL INFILTRATION; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DIASTOLE; HEART DISEASE; HEART HYPERTROPHY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; INFLAMMATION; MACROPHAGE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN INDUCTION; RAT STRAIN; REVIEW; SYSTOLIC BLOOD PRESSURE;

ANIMALS; CORONARY CIRCULATION; DIASTOLE; FIBROSIS; HUMANS; MYOCARDIUM; VASCULITIS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 23944466382     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.28.483     Document Type: Review

References (53)

1. Vasan RS, Benjamin EJ, Levy D: Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995; 26: 1565-1574.
2. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D: Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999; 33: 1948-1955.
3. Tsuchihashi M, Tsutsui H, Kodama K, Kasagi F, Takeshita A: Clinical characteristics and prognosis of hospitalized patients with congestive heart failure - a study in Fukuoka, Japan. Jpn Circ J 2000; 64: 953-995.
4. Tsutsui H, Tsuchihashi M, Takeshita A: Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. Am J Cardiol 2001; 88: 530-533.
5. Mann DL: Mechanisms and models in heart failure. Circulation 1999; 100: 999-1008.
6. Senni M, Tribouilloy CM, Rodeheffer RJ, et al: Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98: 2282-2289.
7. Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865.
8. Brasier AR, Recinos A III, Eledrisi MS: Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002; 22: 1257-1266.
9. Brilla CG, Weber KT: Reactive and reparative myocardial fibrosis in arterial hypertension in the rats. Cardiovasc Res 1992; 26: 671-677.
10. Weber KT, Brilla CG, Janicki JS: Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993; 27: 341-348.
11. Jalil JE, Doering CW, Janicki JS, Pick R, Shroff SG, Weber KT: Fibrillar collagen and myocardial stiffness in intact hypertrophied rat left ventricle. Circ Res 1989; 64: 1041-1050.
12. Swynghedauw B: Molecular mechanisms of myocardial remodeling. Physiol Rev 1999; 79: 215-262.
13. Zile RM, Brutsart DL: New concepts in diastolic dysfunction and diasolic heart failure: part II. Causal mechanisms and treatment. Circulation 2002; 105: 1503-1508.
14. Mandinov L, Eberli FR, Seiler C, Hess OM: Diastolic heart failure. Cardiovasc Res 2000; 45: 813-825.
15. Narayan S, Janicki JS, Shroff SG, Pick R, Weber KT: Myocardial collagen and mechanics after preventing hypertrophy in hypertensive rats. Am J Hypertens 1989; 2: 675-682.
16. Conrad CH, Brooks WW, Hayes JA, Sen S, Robinson KG, Bing OL: Myocardial fibrosis and stiffness with hypertrophy and heart failure in spontaneously hypertensive rats. Circulation 1995; 91: 161-170.
17. Matsubara LS, Matsubara BB, Okoshi MP, Cicogna AC, Janicki JS: Alterations in myocardial collagen content affect rat papillary muscle function. Am J Physiol 2000; 279: H1534-H1539.
18. Yamamoto K, Masuyama T, Sakata Y, et al: Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 2002; 55: 76-82.
19. Burlew BS, Weber KT: Cardiac fibrosis as a cause of diastolic dysfunction. Herz 2002; 27: 92-98.
20. Villarreal FJ, Dillmann WH: Cardiac hypertrophy-induced changes in mRNA levels for TGF-β1, fibronectin and collagen. Am J Physiol 1992; 262: H1861-H1866.
21. Kato S, Spinale FG, Tanaka R, Johnson W, Cooper G IV, Zile MR: Inhibition of collagen cross-linking: effects on fibrillar collagen and ventricular diastolic function. Am J Physiol 1995; 269: H863-H868.
22. Doi R, Masuyama T, Yamamoto K, et al: Development of different phenotypes of hypertensive heart failure: systolic versus diastolic failure in Dahl salt-sensitive rats. J Hypertens 2000; 18: 111-120.
23. Yamamoto K, Masuyama T, Sakata Y, et al: Local neurohumoral regulation in the transition to isolated diastolic heart failure in hypertensive heart disease: absence of AT1 receptor downregulation and 'overdrive' of endothelin system. Cardiovasc Res 2000; 46: 421-432.
24. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Hori M: Prevention of diastolic heart failure by endothelin type A receptor antagonist through inhibition of ventricular structural remodeling in hypertensive heart. J Hypertens 2002; 20: 753-761.
25. Nishikawa N, Yamamoto K, Sakata Y, et al: Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovasc Res 2003; 57: 766-774.
26. Sakata Y, Yamamoto K, Mano T, et al: Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation 2004; 109: 2143-2149.
27. Kuwahara F, Kai H, Tokuda K, et al: Transforming growth factor-β function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002; 106: 130-135.
28. Tahira Y, Fukuda N, Endo M, et al: Transforming growth factor-β expression in cardiovascular organs in stroke-prone spontaneously hypertensive rats with the development of hypertension. Hypertens Res 2002; 25: 911-918.
29. Saito K, Ishizaka N, Aizawa T, et al: Role of aberrant iron homeostasis in the upregulation of transforming growth factor-β1 in the kidney of angiotensin II-induced hypertensive rats. Hypertens Res 2004; 27: 599-607.
30. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-126.
31. Hinglais N, Heudes D, Nicoletti A: Colocalization of myocardial fibrosis and inflammatory cells in rats. Lab Invest 1994; 70: 286-294.
32. Nicoletti A, Heudes D, Mandet C, Hinglais N, Bariety J, Michel JB: Inflammatory cells and myocardial fibrosis: spatial and temporal distribution in renovascular hypertensive rats. Cardiovasc Res 1996; 32: 1096-1107.
33. Komatsu S, Panes J, Russel JM, Anderson DC, Miyasaka M, Granger DN: Effects of chronic arterial hypertension on constitutive and induced intracellular adhesion molecule-1 expression in vivo. Hypertension 1997; 29: 683-689.
34. Kuwahara F, Kai H, Tokuda K, et al: Hypertensive myocardial fibrosis and diastolic dysfunction - another model of inflammation -. Hypertension 2004; 43: 739-745.
35. Kuwahara F, Kai H, Tokuda K, et al: Roles of intercellular adhesion molecule-1 in hypertensive cardiac remodeling. Hypertension 2003; 41: 819-823.
36. Border WA, Nobel NA: Transforming growth factor-β in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292.
37. Reap TJ, Groot PHE: Chemokines and atherosclerosis. Atherosclerosis 1999; 147: 213-225.
38. Nicoletti A, Michel JB: Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc Res 1999; 41: 532-543.
39. Desmoulière A, Geinoz A, Gabbiani F, Gabbiani G: Transforming growth factor-β1 induces α-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Biol Chem 1993; 122: 103-111.
40. Eto M, Toba K, Akishita M, et al: Impact of blood pressure variability on cardiovascular events in elderly patients with hypertension. Hypertens Res 2005; 28: 1-7.
41. Tokuda K, Kai H, Kuwahara F, et al: Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis. Hypertension 2004; 43: 499-503.
42. Capers Q IV, Alexander RW, Lou P, et al: Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension 1997; 30: 1397-1402.
43. Jiang MJ, Yu YJ, Chen YL, Lee YM, Hung LS: Cyclic strain stimulates monocyte chemotactic protein-1 mRNA expression in smooth muscle cells. J Cell Biochem 1999; 76: 303-310.
44. Alexander RW: Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspectives. Hypertension 1995; 25: 155-161.
45. Tokuda K, Kai H, Kuwahara F, Imaizumi T: Sub-depressor dose of angiotensin type-1 receptor blocker inhibits TGF-β-mediated perivascular fibrosis in hypertensive rat hearts. J Cardiovasc Pharmacol 2003; 42 (Suppl): S61-S65.
46. Mervaala EMA, Müller DN, Park J-K, et al: Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 1999; 33: 389-395.
47. Pastore L, Tessitore A, Martinotti S, et al: Angiotensin II stimulates intracellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999; 100: 1646-1652.
48. Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM: Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 1998; 83: 952-959.
49. Hernandez-Presa M, Bustos C, Ortego M, et al: Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997; 95: 1532-1541.
50. Border WA, Ruoslahti E: Transforming growth factor-β in disease: the dark side of tissue repair. J Clin Invest 1992; 90: 1-7.
51. Kurisu S, Ozono R, Oshima T, et al: Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension 2003; 41: 99-107.
52. Mukawa H, Toki Y, Miyazaki Y, Matsui H, Okumura K, Ito T: Angiotensin II type 2 receptor blockade partially negates antihypertrophic effects of type 1 receptor blockade on pressure-overload rat cardiac hypertrophy. Hypertens Res 2003; 26: 89-95.
53. Sato A, Saruta T: Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 2004; 27: 303-310.